standard PPI

PreclinicalSmall molecule

YYonsei University

standard PPI is one of 56 small molecule programs targeting Chronic Cough. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic CoughActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Chronic CoughPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Jesduvroq

GGlaxo Dba Glaxosmithkline

Phase 3

11 2

Uloric

Takeda

Preclinical

2 3

Sovaldi

Gilead

Preclinical

1 4

Glucotrol

Pfizer

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Activase

Flomax

Januvia

ZZydus Therapeutics Inc.

Preclinical

1 10

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

N/ARecruiting

Chronic Kidney Disease

NCT06322056

Clinical

Trials by Indication[1]

Helicobacter Pylori Eradication1 trial

A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide

Withdrawn·YYonsei University·Phase 2·NCT02090738

Chronic Kidney Disease1 trial

Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney Disease

Recruiting·YYonsei University·N/A·NCT06322056·642 enrolled

Chronic Cough1 trial

Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial

Completed·YYonsei University·N/A·NCT01888549·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for standard PPI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — standard PPI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for standard PPI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

standard PPI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Helicobacter Pylori Eradication1 trial

Chronic Kidney Disease1 trial

Chronic Cough1 trial

References

Drug Info

Quick Facts

Related News